Efficacy and Safety of Tamsulosin in the Treatment of Benign Prostatic Hyperplasia
Snjezana Milicevic, Radojka Bijelic
Med Arh. 2012; 66(3): 173-176
Introduction/Objective: The α-adrenergic receptor antagonists represent the most frequently prescribed first line treatment for benign prostatic hyperplasia. Tamsulosin is a uroselective α1A/α1D adrenergic receptor antagonist. The objective of this study is to establish the efficacy and safety of a daily dose of tamsulosin 0.4 mg in patients with functional symptoms of benign prostatic hyperplasia through an evaluation of reduction of subjective symptoms, quantified through the International Prostate Symptom Score. Materials and methods: 45 patients with lower urinary tract symptoms caused by benign prostatic hyperplasia used tamsulosin 0.4 mg over the course of 12 weeks; their International Prostate Symptom Score (IPSS) value was ≥ 8 points, while their Quality of Life Index (QLI) value was ≥ 3 points. Checkups were scheduled 4 and 12 weeks following the initiation of treatment, during which the values for IPSS and disease-specific quality of life (QLI) were obtained. Results: At the beginning of tamsulosin treatment, the total IPSS was 24.95 points. After the 4- and 12-week checkups, the total IPSS fell to 16.09 and 11.20 points, respectively. The reduction in symptoms, quantified through IPSS, was 35.51% after 4 weeks of treatment, and 55.11% after 12 weeks. The Quality of Life Index was initially 4.49 points, it decreased to 2.49 points after 4 weeks, and to 1.40 points after 12 weeks, marking an improvement of 44.54% after 4 weeks and 68.82% after 12 weeks. There was a statistically significant difference between the initial values for IPSS and QLI and their values after both checkups (p<0.05). Side effects were observed in three patients (6.66%), with one (2,22%) experiencing problems with ejaculation and the other two (4,44%) having vasodilatatory effects such as vertigo and headache. Conclusion: Clinical response to a 12-week tamsulosin treatment improved during the course of treatment, reflected in a reduction in all of the lower urinary tract symptoms, with rare and insignificant side effects. .
1. Ravish IR, Nerli RB, Amarkhed SS. Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate. Arch Androl. 2007; 53: 17-20.
2. Calais da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrik DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. EurUrol. 1997; 31: 272-280.
3. Jacobsen SJ, Guess HA, Pamser L et al. A population-based study of health careseeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary symptoms and Health status Among Men. Arch Fam Med. 1993; 2:729-2735
4. Berges RR, Pientka L, Hofner k, Senge T, Jonas U. Male lower urinary tract symptoms and related health care seeking in Germany. Eur Urol. 2001; 39: 682-687.
5. Sarma AV, Jacobsen SJ, Girman CJ et al. Concomitant longitudinal changes in frequency of and bother from lower urinary tract symptoms in community dwelling men. J Urol. 2002; 168: 1446-1452.
6. American Urological Association. Guideline on the Management of benign prostatic hyperplasia (BPH). Linthicum, MD. American Association Education and Research, Inc, 2006.
7. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). EurUrol. 2004; 46: 547-554.
8. Oelke M, Bachmann A, Descazeaud A et al. Guidelines on Conservative Treatment of Non-neurogenic Male LUTS. Available from URL: http:/www.uroweb.org/gls/pdf/BPH%202010.pdf
9. McConnell ID, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003; 349: 2387-2398.
10. Roehrborn CG. Afuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-cotrolled study. BJU Int. 2006; 97: 734-741.
11. Caine M, Pfau A, Perlberg S. The use of αadrenergic blockers in benign prostatic obstruction. Br J Urol. 1976; 48: 255-263.
12. HIeble JP, Bylund DB, Clarke DE et al. Internation Union of Pharmacology X. Recommendation for nomenclature of α1-adrenoreceptors: Concensus update. Pharmacol Rey. 1995; 47: 267-270.
13. Roehrborn CG, Schwinn DA. A-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004; 171: 1029-1035.
14. Anderson KE, Gratxke C. Pharmacology of α1-adrenoreceptor antagonist in the lower urinary tract and central nervous system. Nat Clin Pract Urol. 2007; 4: 368-378.
15. Nordling J, Hald T. BPH versus LUTS: reflections on lower urinary tract symptoms in search of a definition of clinical benign prostatic hyperplasia. EurUrol. 1997; 6: 54-60.
16. Kirby RS, Coppinger SWC, Corcoran MO, Chapple CR, Flannagan M, Milroy EJG. Prazosin in the treatmen of prostatic obstruction: a placebo-control study. Br J Urol. 1987; 60: 136-142.
17. Lepor H, Auerbach S, Puras-Baex A. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatmen of benign prostatic hyperplasia. J Urol. 1992; 148: 1476-1474.
18. Roehrborn CG, Oesterling JE, Arbor A. Hytrin community assessment trial: evaluation of the clinical effectiveness of terazosin versus placebo in the treatment of patients with symptomatic benign hyperplasia. J Urol. 1995; 153 (Suppl): 272
19. Chapple CR, Carter P, Christmas TJ. A three month double-blind placebo controlled study of doxazosin as treatment for benign prostatic bladder outflow obstruction. Br J Urol. 1994; 74: 50-56.
20. Jardin A, Bensadun H, Delauche-Cavallier MC. Long term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. Br J Urol. 1994; 74: 579-584.
21. Yamada S, Tanaka C, Kimura R, Kawabe K. A1-adrenoreceptors in human prostate: characterization and binding characteristics of α-1 antagonist. Life Sci. 1994; 54: 1845-1854.
22. Lepor H. Role of α1-adrenergic blockers in the treatment of benign prostatic hyperplasia. Prostate. 1990; 3: 75-84.
23. Hieble JP, Caine M, Zalaznik E. In vitro characterization of the α-adrenoreceptors in human prostate.Eur J pharmacol. 1985; 107: 111-117.
24. Ford AP, Williams TJ, Blue DR, Clarke DE. A1-adrenoreceptor classification: sharpening Occams razor. Trends Pharmacol Sci. 1994; 15: 167-170.
25. Ikemoto I, Kiyota H, Ohishi Y, Abe K, Goto H, Kishimoto K. Usefulness of tamsulosin hydrochloride et naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative randomized two drug crossover study. Int J Urol. 2003; 10: 578-594.
26. Osamu U, Motohiro K, Atsuko F et al. Naftopidil versus tamsulosin hydrochloride for lower urinary tract cymptoms associated with benign prostatic hyperplasia with special reference to the storage symptoms: A prospective randomized controlled study. Int J Urol. 2008; 15: 1049-1054.
27. Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of α-adrenoreceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004; 64: 1081-1088.